These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 20164150

  • 1. The expression of p38, ERK1 and Bax proteins has increased during the treatment of newly diagnosed acute promyelocytic leukemia with arsenic trioxide.
    Mandegary A, Hosseini R, Ghaffari SH, Alimoghaddam K, Rostami S, Ghavamzadeh A, Ghahremani MH.
    Ann Oncol; 2010 Sep; 21(9):1884-1890. PubMed ID: 20164150
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia.
    Alimoghaddam K, Shariftabrizi A, Tavangar SM, Sanaat Z, Rostami S, Jahani M, Ghavamzadeh A.
    Leuk Lymphoma; 2006 Jan; 47(1):81-8. PubMed ID: 16321832
    [Abstract] [Full Text] [Related]

  • 4. Retrospective study of arsenic trioxide for childhood acute promyelocytic leukemia in China: a single-center experience.
    Wang H, Hao L, Wang X, Li J, Wu Q, Bian S.
    Int J Hematol; 2010 Jun; 91(5):820-5. PubMed ID: 20461563
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.
    Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, Coutré S, Dahlberg S, Ellison R, Warrell RP.
    J Clin Oncol; 2001 Sep 15; 19(18):3852-60. PubMed ID: 11559723
    [Abstract] [Full Text] [Related]

  • 8. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.
    Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP.
    N Engl J Med; 1998 Nov 05; 339(19):1341-8. PubMed ID: 9801394
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies.
    Chou WC, Dang CV.
    Curr Opin Hematol; 2005 Jan 05; 12(1):1-6. PubMed ID: 15604884
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.
    Zhu HH, Wu DP, Jin J, Li JY, Ma J, Wang JX, Jiang H, Chen SJ, Huang XJ.
    J Clin Oncol; 2013 Nov 20; 31(33):4215-21. PubMed ID: 24127444
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.